{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:40:41Z","timestamp":1793338841311,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.intimp.2025.114596","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T11:12:49Z","timestamp":1743678769000},"page":"114596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy and safety of telitacicept in patients with class III\u2013V lupus nephritis: A real-world retrospective cohort study"],"prefix":"10.1016","volume":"154","author":[{"given":"Lin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2025.114596_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2025.114596_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119894","article-title":"Precision medicine in lupus nephritis","volume":"562","author":"Sharafaldin","year":"2024","journal-title":"Clin. Chim. Acta"},{"issue":"17","key":"10.1016\/j.intimp.2025.114596_bb0015","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2025.114596_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102871","article-title":"Lupus nephritis: new progress in diagnosis and treatment","volume":"132","author":"Yu","year":"2022","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.intimp.2025.114596_bb0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.114596_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2025.114596_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1050528","article-title":"B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease","volume":"14","author":"Giordano","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114596_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114596_bb0045","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.114596_bb0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int."},{"issue":"19","key":"10.1016\/j.intimp.2025.114596_bb0055","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1S","key":"10.1016\/j.intimp.2025.114596_bb0060","first-page":"S1","article-title":"Improving global outcomes lupus nephritis work G. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Disease","year":"2024","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.intimp.2025.114596_bb0065","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114596_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheum."},{"issue":"10289","key":"10.1016\/j.intimp.2025.114596_bb0075","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.intimp.2025.114596_bb0080","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.intimp.2025.114596_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114596_bb0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2025.114596_bb0095","doi-asserted-by":"crossref","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study","author":"Huang","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114596_bb0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4049\/jimmunol.2101107","article-title":"Features of isoforms of human soluble TACI","volume":"211","author":"Fichtner","year":"2023","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114596_bb0105","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2025.114596_bb0110","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114596_bb0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population","volume":"81","author":"Yu","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.intimp.2025.114596_bb0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","article-title":"The role of APRIL \u2013 A proliferation inducing ligand \u2013 In autoimmune diseases and expectations from its targeting","volume":"95","author":"Baert","year":"2018","journal-title":"J. Autoimmun."},{"issue":"Suppl. 79","key":"10.1016\/j.intimp.2025.114596_bb0125","article-title":"Telitacicept, a human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), in systemic lupus erythematosus (SLE): results of a phase 3 study [abstract]","volume":"74","author":"Wu","year":"2022","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2025.114596_bb0130","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2025.114596_bb0135","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol."},{"issue":"11\u221212","key":"10.1016\/j.intimp.2025.114596_bb0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000533847","article-title":"Clinicopathological characteristics and prognosis of lupus nephritis patients with acute kidney injury","volume":"54","author":"Li","year":"2023","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.intimp.2025.114596_bb0145","doi-asserted-by":"crossref","first-page":"1423035","DOI":"10.3389\/fimmu.2024.1423035","article-title":"Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study","volume":"15","author":"Fan","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114596_bb0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.2005.041673","article-title":"Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment","volume":"65","author":"Giannouli","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2025.114596_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2016.07.001","article-title":"The diagnosis and management of the haematologic manifestations of lupus","volume":"74","author":"Velo-Garcia","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2025.114596_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-225563","article-title":"Correspondence on \u2018EULAR recommendations for the management of systemic lupus erythematosus: 2023 update\u2019 by Fanouriakis et al","author":"Kronbichler","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2025.114596_bb0165","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2215\/CJN.10601016","article-title":"Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis","volume":"12","author":"Rijnink","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114596_bb0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-024-00951-7","article-title":"Obesity and the kidney: mechanistic links and therapeutic advances","volume":"20","author":"Yau","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114596_bb0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13679-023-00500-9","article-title":"The fat kidney","volume":"12","author":"Verde","year":"2023","journal-title":"Curr. Obes. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2025.114596_bb0180","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as cardiovascular risk factor in chronic kidney disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ. Res."},{"key":"10.1016\/j.intimp.2025.114596_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109946","article-title":"Immunometabolomics provides a new perspective for studying systemic lupus erythematosus","volume":"118","author":"Wu","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114596_bb0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/clinchem\/hvaa242","article-title":"LDL-cholesterol versus glucose in microvascular and macrovascular disease","volume":"67","author":"Emanuelsson","year":"2021","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.114596_bb0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T23:51:12Z","timestamp":1744501872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925005867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":39,"alternative-id":["S1567576925005867"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114596","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of telitacicept in patients with class III\u2013V lupus nephritis: A real-world retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114596"}}